Hemoglobinopathy: Difference between revisions

Jump to navigation Jump to search
Line 29: Line 29:
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.<ref name="pmid21886666">{{cite journal |vauthors=Kohne E |title=Hemoglobinopathies: clinical manifestations, diagnosis, and treatment |journal=Dtsch Arztebl Int |volume=108 |issue=31-32 |pages=532–40 |date=August 2011 |pmid=21886666 |pmc=3163784 |doi=10.3238/arztebl.2011.0532 |url=}}</ref>


===Prevalence===
===Prevalence===
*In 2008, the prevalence of hemoglobinopathy was estimated to be 7% of the  worldwide population  being carrier.
*In 2008, the prevalence of hemoglobinopathy was estimated to be 7% of the  worldwide population  being carrier.<ref name="pmid218866662">{{cite journal |vauthors=Kohne E |title=Hemoglobinopathies: clinical manifestations, diagnosis, and treatment |journal=Dtsch Arztebl Int |volume=108 |issue=31-32 |pages=532–40 |date=August 2011 |pmid=21886666 |pmc=3163784 |doi=10.3238/arztebl.2011.0532 |url=}}</ref>


===Race===
===Race===
'''α-thalassemias'''
'''α-thalassemias'''


It occure cur mainly in Africa, Arab nations, and, more frequently and South-East Asia.<ref name="pmid20186311">{{cite journal |vauthors=Kohne E, Kleihauer E |title=Hemoglobinopathies: a longitudinal study over four decades |journal=Dtsch Arztebl Int |volume=107 |issue=5 |pages=65–71 |date=February 2010 |pmid=20186311 |pmc=2828242 |doi=10.3238/arztebl.2010.0065 |url=}}</ref>
It occure cur mainly in Africa, Arab nations, and, more frequently and South-East Asia.


'''β-thalassemias'''
'''β-thalassemias'''

Revision as of 16:35, 31 August 2018

Template:Search infobox Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]


Overview

Hemoglobinopathy is a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Most common hemoglobinopathies include sickle-cell disease.

Classification

Hemoglobinopathy be classified according to genetic and structure of hemoglobin into two main groups:

  • Thalassemia syndromes
    • α-thalassemia
    • β-thalassemia
  • Structural hemoglobin variants
    • HbS
    • HbE
    • HbC
    • Hb Bart’s
    • Hb J(Johnstown)
    • HbM
    • HbX
    • Hb D


Migration patterns

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.[1]

Prevalence

  • In 2008, the prevalence of hemoglobinopathy was estimated to be 7% of the worldwide population being carrier.[2]

Race

α-thalassemias

It occure cur mainly in Africa, Arab nations, and, more frequently and South-East Asia.

β-thalassemias

It occure cur mainly in Mediterranean countries, South-East Europe, Arab nations and Asia.

Screening

Common variants

  • Hb S
  • Hb C
  • Hb E
  • Hb D-Punjab
  • Hb O-Arab
  • Hb G-Philadelphia
  • Hb Hasharon
  • Hb Korle-Bu
  • Hb Lepore
  • Hb M

Hemoglobinopathy and evolution

de:Hämoglobinopathie nl:Hemoglobinopathie

Template:Hematology


Template:WikiDoc Sources

  1. Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
  2. Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.